HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Class Action Blight: The Sour Side Of Apple Stem Cell Anti-Aging Boom

This article was originally published in The Rose Sheet

Executive Summary

Plant stem cell actives such as Mibelle Biochemistry's PhytoCellTec Malus Domestica were marquee ingredients for skin-care brands in the flourishing US anti-aging market years back. But what once was fruitful has turned rotten with regulatory crackdowns in recent years and class actions that continue to weigh on product manufacturers.

You may also be interested in...



Adore Settles With Nationwide Class Over Apple Stem Cell Anti-Aging Claims

The estimated $700,000 settlement puts to rest allegations that the luxury skin-care firm deceived consumers with claims about its PhytoCellTec ingredient’s ability to slow the aging process. G.M. Collin, another PhytoCellTec Malus Domestica user, also appears to have reached a deal with plaintiffs in litigation challenging its anti-aging claims.

FDA Warnings Slow, But Anti-Aging Claims Remain Class Action Targets

The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.

FTC-L’Oreal Settlement Will Fuel Cosmetics Class Actions – Attorney

Class actions against cosmetics firms show no sign of slowing down, and FTC’s pending settlement with L’Oreal for gene-related anti-aging claims likely will spur further litigation in the sector, Edwards Wildman Palmer partner Ronie Schmelz says.

Related Content

Topics

UsernamePublicRestriction

Register

RS109310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel